NASDAQ: ONCTOncternal Therapeutics Inc Stock
$8.55-0.31 (-3.5%)
Updated Apr 22, 2024
ONCT Price
$8.55
Fair Value Price
$0.48
Market Cap
$25.30M
52 Week Low
$5.57
52 Week High
$13.14
P/E
-0.64x
P/B
0.84x
P/S
40.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$785.00k
Earnings
-$39.48M
Gross Margin
100%
Operating Margin
-5,029.17%
Profit Margin
-5,029.2%
Debt to Equity
0.22
Operating Cash Flow
-$32M
Beta
0.96
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ONCT Overview
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ONCT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ONCT ($8.55) is overvalued by 1,669.11% relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ONCT ($8.55) is not significantly undervalued (1,669.11%) relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ONCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ONCT due diligence checks available for Premium users.
Be the first to know about important ONCT news, forecast changes, insider trades & much more!
ONCT News
Valuation
ONCT fair value
Fair Value of ONCT stock based on Discounted Cash Flow (DCF)
Price
$8.55
Fair Value
$0.48
Overvalued by
1,669.11%
ONCT ($8.55) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ONCT ($8.55) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ONCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ONCT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.64x
Industry
16.21x
Market
41x
ONCT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.84x
Industry
5.82x
ONCT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ONCT's financial health
Profit margin
Revenue
$297.0k
Net Income
-$9.2M
Profit Margin
-3,085.5%
ONCT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ONCT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$36.7M
Liabilities
$6.7M
Debt to equity
0.22
ONCT's short-term assets ($36.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONCT's short-term assets ($36.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONCT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ONCT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.4M
Investing
-$1.8M
Financing
-$1.0k
ONCT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ONCT vs Biotech Stocks
Oncternal Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.